Literature DB >> 23051015

An analysis of the high psychotropic off-label use in psychiatric disorders The majority of psychiatric diagnoses have no approved drug.

Kavi K Devulapalli1, Henry A Nasrallah.   

Abstract

OBJECTIVE: The authors' goals were to determine the extent of unapproved indications in the DSM-IV-TR, to highlight common off-label uses of psychotropic medications and offer insights into the rationale of the widespread off-label prescribing in psychiatry.
METHOD: Indications for approved psychotropic agents, obtained from the Physicians Desk Reference and the Drug Information Handbook, Clinical Handbook of Psychotropic Drugs, 15th edition, and the Drugs@FDA online database were analyzed in the context of the DSM-IV-TR to determine the percent of DSM-IV-TR disorders that are indications for psychotropic agents. A literature search was performed to determine common off-label uses of major classes of psychotropic medications.
RESULTS: 88.5% of all DSM-IV-TR categorized disorders lack an approved medication for their treatment. Atypical Antipsychotics had the most extensive off-label use for DSM-IV-TR categorized disorder, whereas Mood Stabilizers showed the greatest off-label use with regards to disorders and symptoms that are not DSM-IV classified. For each class of medications, more off-label uses exist than FDA-approved uses.
CONCLUSIONS: The vast majority of DSM-IV-TR categorized disorders lack approved medications for their treatment. The large unmet need for approved psychiatric indications may explain the widespread off-label use of psychotropic medications in clinical practice.

Entities:  

Year:  2009        PMID: 23051015     DOI: 10.1016/j.ajp.2009.01.005

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  7 in total

1.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

2.  Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.

Authors:  Gudrun Hefner; Jan Wolff; Sermin Toto; Pamela Reißner; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2022-09-07       Impact factor: 3.850

Review 3.  New drug developments in psychosis: Challenges, opportunities and strategies.

Authors:  Matcheri S Keshavan; Ashley N Lawler; Henry A Nasrallah; Rajiv Tandon
Journal:  Prog Neurobiol       Date:  2016-08-09       Impact factor: 11.685

4.  Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe.

Authors:  Jeana Frost; Sally Okun; Timothy Vaughan; James Heywood; Paul Wicks
Journal:  J Med Internet Res       Date:  2011-01-21       Impact factor: 5.428

5.  Off-label Psychotropics Use: Isn't it Now an Inevitable and a "Norm" in Psychiatry?

Authors:  Sourav Khanra; Basudeb Das
Journal:  Indian J Psychol Med       Date:  2018 Jul-Aug

6.  Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital.

Authors:  Jeroen Govaerts; Julie Boeyckens; Astrid Lammens; Annelies Gilis; Filip Bouckaert; Marc De Hert; Jan De Lepeleire; Brendon Stubbs; Franciska Desplenter
Journal:  Ther Adv Psychopharmacol       Date:  2021-03-19

7.  Off-label drug use in Psychiatry Outpatient Department: A prospective study at a Tertiary Care Teaching Hospital.

Authors:  Darshan Kharadi; Kamlesh Patel; Devang Rana; Varsha Patel
Journal:  J Basic Clin Pharm       Date:  2015-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.